Progress in the non-Hodgkin's lymphomas

Annals of Oncology

Volumn 10, Issue SUPPL. 6, 1999, Pages

  Yuen, Allan R ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MITOXANTRONE; PREDNISONE; RITUXIMAB; VALSPODAR; VERAPAMIL; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CEREBELLAR ATAXIA; CHILL; CONFERENCE PAPER; FEVER; HUMAN; HYPOTENSION; MOUSE; MULTIDRUG RESISTANCE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

EID: 0033387608     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_6.S19     Document Type: Conference Paper

References (19)

1. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102: 596-602.
2. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-6.
3. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-94.
4. Haioun C, Lepage E, Gisselbrecht C et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1131-7.
5. Gisselbrecht C, Lepage E, Morel P et al. Short and intensified treatment with autologous stem cell transplantation versus ACVB regimen in poor prognosis aggressive lymphoma. Prognostic factors of induction failure. Proc. International Congress on Lymphomas Lugano, Switzerland, 1996.
6. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290-7.
7. Lopez GA, Montserrat E, Bosch F et al. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994; 12: 1343-8.
8. Ansell SM, Habermann TM, Kurtin PJ et al. Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 1997; 15: 2296-301.
9. Maloney DG, Grillo LA, White CA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-95.
10. Pastan I, Gottesman M. Multidrug resistance in human cancer. N Engl J Med 1987; 316: 1388-93.
11. Ueda K, Cardarelli C, Gottesman M et al. Expression of a full-length cDNA for the human mdrl gene confers resistance to colchicine. doxorubicin and vinblastine. Proc Natl Acad Sci 1987; 84: 3004-8.
12. Goldstein LJ, Galski H, Fojo A et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116-24.
13. Cheng AL, Su IJ, Chen YC et al. Expression of P-glycoprotein and glulathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J Clin Oncol 1993; 11: 109-15.
14. Miller TP, Grogan TM, Dalton WS et al. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991; 19: 17-24.
15. Gascoyne R, Tolcher A, Van Iderstine E et al. The prognostic relevance of p-glycoprotein expression in malignant lymphomas. Proc General Motors Cancer Research Foundation International Symposium, Toronto, Canada: 1993; abstract A7.
16. Pileri SA, Sabattini E, Falini B et al. Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology 1991; 19: 131-40.
17. Wilson W, Bates S, Kang Y et al. Reversal of multidrug resistance (mdr-1) with R-verapamil and analysis of mdr-1 expression in patients with lymphoma refractory to EPOCH chemotherapy. Proc Am Assoc Cancer Res 1993; 34: 212.
18. Twentyman P, Bleehen N. Resistance modification by PSC833, a novel non-immunosuppressive cyclosporin A. Eur J Cancer 1991; 27: 1639-42.
19. Chao N, Rosenberg S, Horning S. CEPP(B). An effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. Blood 1990; 76: 1293-8.